Search bioRxiv⌕ Search

Biology subjects

Lo, E. K. K.

Publications and source records attributed to Lo, E. K. K..

2 recordsLinked to original sources

Associations Between Gut Microbiome and 24-Hour Blood Pressure Variability: A Cross-sectional Study Highlighting Sex Differences and Potential Therapeutic Targets

Blood pressure (BP) variability is an independent risk factor for cardiovascular disease (CVD). While gut microbiota (GM) and GM-derived short-chain fatty acids (SCFAs) are recognized to play a key role in BP regulation, their association with BP variability remains poorly understood. This cross-sectional study of 241 community-dwelling individuals from Hong Kong (113 men and 128 women, mean age 54{+/-}6 years) without symptomatic CVD examined the associations of GM, characterized by shotgun sequencing, and plasma SCFAs, with systolic and diastolic blood pressure (SBP/DBP) variability assessed by 24-hour BP monitoring. GM analyses, using covariate-adjusted statistical models, revealed that higher 24-hour SBP CoV associated negatively with GM -diversity (Shannon and Simpsons index, P<0.05) and positively with Firmicutes/Bacteroidetes ratio, driven by the female cohort. Parabacteroides merdae, Bacteroides dorei, Bifidobacterium pseudocatenulatum, Alistipes finegoldii and Bacteroides intestinalis were negatively associated with indices of SBP/DBP variability in a sex-specific manner. Further analysis indicated that B. dorei may mediate SBP CoV via plasma iso-butyric acid in women (bootstrapping 95% CI: -3.6 to -0.19; P<0.05). We demonstrated that higher SBP variability is associated with markers of gut dysbiosis and a reduction in beneficial gut bacteria, particularly in women. Notably, we identified several gut bacterial species with potential therapeutic implications for managing 24-hour SBP/DBP variability, warranting further investigation.

microbiology↗

Mechanistic insights into zearalenone-accelerated colorectal cancer in mice using integrative multi-omics approaches

Zearalenone (ZEA), a secondary metabolite of Fusarium fungi found in cereal-based foods, promotes the growth of colon, breast, and prostate cancer cells in vitro. However, the lack of animal studies hinders a deeper mechanistic understanding of the cancer-promoting effects of ZEA. This study aimed to determine the effect of ZEA on colon cancer progression and its underlying mechanisms. Through integrative analyses of transcriptomics, metabolomics, metagenomics, and host phenotypes, we investigated the impact of a 4-week ZEA intervention on colorectal cancer in xenograft mice. Our results showed a twofold increase in tumor weight with the 4-week ZEA intervention. ZEA exposure significantly increased the mRNA and protein levels of BEST4, DGKB, and Ki67 and the phosphorylation levels of ERK1/2 and AKT. Serum metabolomic analysis revealed that the levels of amino acids, including histidine, arginine, citrulline, and glycine, decreased significantly in the ZEA group. Furthermore, ZEA lowered the alpha diversity of the gut microbiota and reduced the abundance of nine genera, including Tuzzerella and Rikenella. Further association analysis indicated that Tuzzerella was negatively associated with the expression of BEST4 and DGKB genes, serum uric acid levels, and tumor weight. Additionally, circulatory hippuric acid levels positively correlated with tumor weight and the expression of oncogenic genes, including ROBO3, JAK3, and BEST4. Altogether, our results indicated that ZEA promotes colon cancer progression by enhancing the BEST4/AKT/ERK1/2 pathway, lowering circulatory amino acid concentrations, altering gut microbiota composition, and suppressing short chain fatty acids production.

cancer biology↗